Compare Neurocrine Biosciences Inc (NBIX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Under Armour Inc Class A — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Under Armour Inc Class A trades at $5.07 (market cap $2.15B). The key difference: Neurocrine Biosciences Inc is far larger — about 7.3× Under Armour Inc Class A's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| NBIX | UAA | |
|---|---|---|
Market Cap | $15.77B | $2.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $8.14 |
52-Week Low | $123.10 | $4.17 |
Enterprise Value | $15.78B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Under Armour (UAA) trades at $5.06, down 3.62% on the day, reflecting persistent investor concerns. The stock is technically bearish, with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $201.27 million in 2025, with revenue declining to $5.16 billion. Recent news highlights a reduced revenue outlook for fiscal 2027, though cost discipline aims to preserve profitability.
The outlook remains challenging due to weak North American demand and falling revenue projections. Analyst consensus is a 'Hold' with a $6.67 price target, indicating cautious optimism for margin recovery. Key risks include sustained sales weakness and high debt levels. The stock offers potential upside if margin improvements materialize, but near-term headwinds dominate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
